Procurement Resource Logo
    • Complexity Reduction Tool
    • Digital Should Cost Model
    • Procure 360
    • Sourcing Compass
    • Spend Analytics
    • Sustainability Tracker
    • Pricing Dashboard
  • Industries
    • Agriculture & Farming Commodities
    • Chemicals
    • Energy, Metals and Minerals
    • Flavours and Fragrances
    • Food and Beverages
    • Healthcare
    • Machinery, Electronics and Durables
    • Operating Costs, Logistics and Utilities
    • Packaging
  • Services
    • Category Compass
    • Commodity Compass
    • Supplier Compass
    • Data Analytics & Automation
    • Digital Solutions
    • Blogs
    • News & Articles
    • Newsletter
    • Manufacturing Plant Project Report3000+
    • Production Cost Report2000+
    • Price Trends1000+
Social Media Icon of linkedinCall Support IconSearch Icon
Login

Newsletter

Get Latest News About Procurement Resource Subscribe for News

Industries

  • Agriculture & Farming Commodities
  • Chemicals
  • Energy, Metals and Minerals
  • Flavours and Fragrances
  • View All

Services

  • Category Compass
  • Commodity Compass
  • Supplier Compass
  • Data Analytics & Automation
  • Digital Solutions
  • View All

Useful Links

  • Testimonial
  • Press Releases
  • About Us
  • Careers
  • Who We Are
  • Term Of Use
  • Contact Us

Solutions

  • How We Work
  • Tail Spend Management
  • Full Time Engagement
  • Custom Research
  • Subscriptions
  • Resource Center
  • Return/Refund Policy
Copyright © 2026 Procurement Resource. All rights reserved.
  • Social Media icon Twitter i.e X
  • Social Media icon instagram i.e insta
  • Social Media icon linkedin i.e in
  • Social Media icon facebook i.e fb

News and Articles

  1. Home/
  2. News and Articles/
  3. The National Pharmaceutical Pricing Authority Slashes the Prices for 35 crucial drugs

The National Pharmaceutical Pricing Authority Slashes the Prices for 35 crucial drugs

Blog Detail Image
Aug 5, 2025
˜ Prakhar Panchbhaiya
  • The NPPA has reduced prices of 35 essential drugs, including anti-inflammatory, cardiovascular, antibiotic, anti-diabetic, and psychiatric medicines.
  • Key affected drugs include Aceclofenac-Paracetamol combinations, Atorvastatin, Amoxycillin-Clavulanate, and newer anti-diabetics like Empagliflozin and Sitagliptin.
  • Pediatric medicines like Cefixime-Paracetamol suspensions and Vitamin D drops are also covered.
  • Retailers must display updated prices, with penalties for overcharging under DPCO 2013 and the Essential Commodities Act.
  • The revised prices exclude GST, and manufacturers must update pricing through Form V submissions.
  • The NPPA regulates drug pricing under the Ministry of Chemicals & Fertilisers to ensure affordability.

India's National Pharmaceutical Pricing Authority (NPPA) has implemented significant price cuts for 35 essential drugs spanning critical therapeutic areas to enhance medicine affordability. The sweeping reforms, approved by the Ministry of Chemicals and Fertilisers, target vital medications including pain relievers, heart disease treatments, antibiotics, diabetes drugs, and mental health prescriptions - offering substantial relief to chronic disease patients.

The comprehensive pricing overhaul affects some of India's most commonly prescribed medicines. Notable reductions include popular combinations like Aceclofenac-Paracetamol (now priced between Rs. 13-15.01 per tablet depending on manufacturer), life-saving cardiovascular drugs such as Atorvastatin-Clopidogrel (capped at Rs.25.61 per tablet), and advanced diabetes treatments combining Empagliflozin, Sitagliptin and Metformin. The policy extends its benefits to vulnerable populations through pediatric formulations like Cefixime-Paracetamol suspensions and essential injectables including Diclofenac (Rs. 31.77/ml).

Strict enforcement mechanisms accompany these revisions. All pharmacies must visibly display the updated pricing, with stringent penalties including financial repercussions for non-compliance under the Drugs (Prices Control) Order 2013. The new prices (GST-exclusive) require immediate implementation, with pharmaceutical firms mandated to update their systems through the Integrated Pharmaceutical Database Management System and submit revised Form V documentation to regulatory bodies.

Read More About Paracetamol Production Cost Reports - Request Free Sample Copy in PDF

This decisive action by India's premier drug pricing authority represents a significant stride in balancing healthcare accessibility with quality standards. By systematically overhauling pricing structures across both scheduled and non-scheduled medicines, the NPPA reinforces its commitment to affordable healthcare while maintaining rigorous pharmaceutical standards nationwide. The move is expected to particularly benefit long-term medication users and economically vulnerable patients across India's healthcare landscape.

The drugs that have been impacted by the latest price revisions are as follows:

  • Aceclofenac + Paracetamol + Trypsin Chymotrypsin
  • Amoxycillin + Potassium Clavulanate
  • Atorvastatin + Clopidogrel
  • Empagliflozin + Metformin
  • Sitagliptin + Metformin
  • Cefixime + Paracetamol (oral suspension)
  • Cholecalciferol (Vitamin D) drops
  • Diclofenac Injection
  • Pantoprazole + Domperidone
  • Rabeprazole + Domperidone
  • Ambroxol + Guaiphenesin + Terbutaline
  • Acebrophylline + Levocetirizine
  • Bilastine + Montelukast
  • Cefpodoxime + Clavulanic Acid
  • Cefuroxime + Potassium Clavulanate
  • Ofloxacin + Ornidazole
  • Azithromycin + Ambroxol
  • Moxifloxacin + Ketorolac
  • Paracetamol + Phenylephrine + Caffeine
  • Nimesulide + Paracetamol
  • Aceclofenac + Paracetamol
  • Glimepiride + Metformin + Pioglitazzne
  • Metformin + Voglibose
  • Linagliptin + Metformin
  • Teneligliptin + Metformin
  • Atorvastatin + Fenofibrate
  • Rosuvastatin + Fenofibrate
  • Telmisartan + Metoprolol
  • Olmesartan + Amlodipine + Hydrochlorothiazide
  • Escitalopram + Clonazepam
  • Paroxetine + Clonazepam
  • Clonazepam + Propranolol
  • Amitriptyline + Chlordiazepoxide
  • Fluoxetine + Olanzapine
  • Risperidone + Trihexyphenidyl

Recent News & Articles

Class III Milk Forecast Lifted to $17.00/cwt on Cheese and Whey Strength
Class III Milk Forecast Lifted to $17.00/cwt on Cheese and Whey Strength
Cheese Procurement Outlook: Spot Prices Ease, Annual Forecasts Rise
Cheese Procurement Outlook: Spot Prices Ease, Annual Forecasts Rise
Coconut Oil Procurement Outlook Improves as Export Supply Grows
Coconut Oil Procurement Outlook Improves as Export Supply Grows
Rapeseed Oil Supply Outlook Improves as Canada Stocks Rise
Rapeseed Oil Supply Outlook Improves as Canada Stocks Rise
Sunflower Oil Supply Rebuild Coming as Ukraine Output Jumps 19 Percent
Sunflower Oil Supply Rebuild Coming as Ukraine Output Jumps 19 Percent

Tags

#Commodity Prices
#Commodity Prices
#Commodities
#Commodities
#Industrial News
#Industrial News
#Gold
#Gold
#Chemicals
#Chemicals
#Outlook for Potassium Carbonate
#Outlook for Potassium Carbonate
#US Steel Scrap Prices
#US Steel Scrap Prices
#USDA Milk Forecast
#USDA Milk Forecast
#Cheese Prices
#Cheese Prices
#Agriculture Raised
#Agriculture Raised
  • Access independent price trends and market intelligence for thousands of raw materials.
  • Request customised production cost and prefeasibility reports for specific plants or locations.
  • Explore subscription dashboards for continuous tracking of prices, indices, and news.
  • Commission bespoke research on categories, suppliers, or trade flows tailored to your brief.

Our Team will be happy to assist you

We are Just a Text away

Read other news in this category

Market Observed a Sluggish Trend for Tryptophan during December 2023
Market Observed a Sluggish Trend for Tryptophan during December 2023
Price Trends of Magnesium Chloride Witnessed a Sluggish Market during December 2023
Price Trends of Magnesium Chloride Witnessed a Sluggish Market during December 2023
Ibuprofen Price Trend Remains Stable Throughout December 2023
Ibuprofen Price Trend Remains Stable Throughout December 2023
To allow an expansion project, Evonik will shut down its Singapore methionine plant
To allow an expansion project, Evonik will shut down its Singapore methionine plant
DSM Announced Production Curbs for Vitamin A in Switzerland Due to Higher Energy Costs
DSM Announced Production Curbs for Vitamin A in Switzerland Due to Higher Energy Costs